CG
PLRX icon

Cutler Group’s Pliant Therapeutics PLRX Stock Holding History

Cutler Group’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-900
Closed -$16K – 3273
2023
Q4 		$16K Sell
900
-100
-10% -$1.52K ﹤0.01% 2107
2023
Q3 		$17K Hold
1,000
– – ﹤0.01% 2154
2023
Q2 		$18K Sell
1,000
-2,227
-69% -$52.7K ﹤0.01% 1911
2023
Q1 		$85K Buy
3,227
+1,127
+54% +$32.1K 0.01% 1049
2022
Q4 		$40K Buy
2,100
+1,800
+600% +$37.6K ﹤0.01% 1731
2022
Q3 		$6K Sell
300
-600
-67% -$11.5K ﹤0.01% 3539
2022
Q2 		$7K Buy
+900
New +$5.76K ﹤0.01% 3484

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Cutler Group's PLRX Position: Q1 2024 in Review

Cutler Group sold out of Pliant Therapeutics (PLRX) in Q1 2024, closing a stake of 900 shares — an estimated $16K sold.

Cutler Group first reported a position in PLRX in Q2 2022 and held it in 7 quarters. The position peaked at $85K in Q1 2023. 135 funds tracked by Wall St. Rank hold PLRX as of Q1 2024.

  • Cutler Group reported no remaining Pliant Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 900 Pliant Therapeutics shares in Q1 2024, an estimated $16K.
  • Cutler Group first reported a position in Pliant Therapeutics in Q2 2022 and held it in 7 quarters.
  • Cutler Group's Pliant Therapeutics position peaked at $85K in Q1 2023.
  • 135 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.